Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Peptic diseases].

D Vouillamoz1, F Viani, P Jornod

  • 1Service de gastro-entérologie et d'hépatologie, BH-10, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|March 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Site-specific recognition of SARS-CoV-2 nsp1 protein with a tailored titanium dioxide nanoparticle.

bioRxiv : the preprint server for biology·2021
Same author

Surgical technique for placement of the automated low flow ascites pump (Alfapump).

Langenbeck's archives of surgery·2020
Same author

[Digestive foreign body management].

Revue medicale suisse·2015
Same author

A novel gene expression signature in peripheral blood mononuclear cells for early detection of colorectal cancer.

Alimentary pharmacology & therapeutics·2014
Same author

Note: High resolution alternating current/direct current Harman technique.

The Review of scientific instruments·2013
Same author

[Radiofrequency ablation for Barret's esophagus].

Revue medicale suisse·2013
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

In 2004, sequential treatment achieved 95% Helicobacter pylori eradication. COX-2 inhibitors reduced gastrointestinal issues but raised cardiac concerns, prompting a return to non-specific NSAIDs with PPIs for high-risk patients.

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • The year 2004 saw significant advancements in therapeutic strategies for common medical conditions.
  • Helicobacter pylori infections and the management of anti-inflammatory treatments were key areas of focus.

Purpose of the Study:

  • To summarize key therapeutic developments from 2004.
  • To evaluate the efficacy and safety of treatments for H. pylori infection and NSAID-induced side effects.

Main Methods:

  • Review of therapeutic outcomes and clinical observations from 2004.
  • Analysis of eradication rates for H. pylori sequential treatment.
  • Assessment of gastrointestinal and cardiac side effects associated with COX-2 inhibitors and NSAIDs.

Main Results:

Related Experiment Videos

  • Sequential treatment protocols for Helicobacter pylori infection demonstrated a 95% eradication rate.
  • Cyclooxygenase-2 (COX-2) inhibitors significantly decreased gastrointestinal side effects compared to traditional anti-inflammatory drugs.
  • Concerns regarding cardiac adverse events associated with certain COX-2 inhibitors emerged, questioning their widespread use.

Conclusions:

  • Sequential H. pylori treatment is highly effective.
  • While COX-2 inhibitors offer gastrointestinal benefits, their cardiac risks necessitate careful patient selection.
  • For patients at risk of NSAID-induced gastrointestinal toxicity, a combination of non-specific NSAIDs and proton pump inhibitors (PPIs) is a viable alternative treatment strategy.